Affymax Anticipates Broad Opportunity For Omontys With Both Small And Large Dialysis Providers
With FDA’s March 27 approval of peginesatide to prevent anemia in CKD patients on dialysis, Affymax will focus initially on marketing to smaller, price-conscious dialysis providers. But the biotech also expects to do business with Fresenius and, to a lesser degree, Davita.
You may also be interested in...
Affymax investors were not pleased with the country’s largest dialysis provider pausing its pilot program of Omontys, but Affymax and analysts are bullish on prospects of a long-term contract developing.
It’s not usually the case in biotech, but investors are showing patience for Affymax as it ramps up the launch of its long-acting erythropoiesis stimulating agent Omontys. The drug has yielded nominal sales since its launch in May but Affymax’s stock is up 25% since the drug was approved March 27.
Dialysis provider DaVita acquires one of the largest independent physician associations, HealthCare Partners, for $4.4 billion in cash and stock, as well as earn-outs.